KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Amortization - Deferred ChargesCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Gsk (GSK) Receivables - Net (2016 - 2025)

Gsk has reported Receivables - Net over the past 10 years, most recently at $9.9 billion for Q4 2025.

  • For Q4 2025, Receivables - Net rose 13.26% year-over-year to $9.9 billion; the TTM value through Dec 2025 reached $9.9 billion, up 13.26%, while the annual FY2025 figure was $9.9 billion, 13.26% up from the prior year.
  • Receivables - Net for Q4 2025 was $9.9 billion at Gsk, up from $8.8 billion in the prior quarter.
  • Over five years, Receivables - Net peaked at $10.6 billion in Q4 2021 and troughed at $8.3 billion in Q4 2022.
  • A 5-year average of $9.3 billion and a median of $9.2 billion in 2023 define the central range for Receivables - Net.
  • Biggest five-year swings in Receivables - Net: increased 15.42% in 2021 and later fell 21.92% in 2022.
  • Year by year, Receivables - Net stood at $10.6 billion in 2021, then fell by 21.92% to $8.3 billion in 2022, then grew by 10.8% to $9.2 billion in 2023, then decreased by 4.28% to $8.8 billion in 2024, then increased by 13.26% to $9.9 billion in 2025.
  • Business Quant data shows Receivables - Net for GSK at $9.9 billion in Q4 2025, $8.8 billion in Q4 2024, and $9.2 billion in Q4 2023.